BALTIMORE, Md., Aug. 8, 2016 /PRNewswire/ -- Personal Genome
Diagnostics Inc. (PGDx), a leading provider of advanced cancer
genome testing products and services, today announced an agreement
with Illumina, Inc. (NASDAQ: ILMN) to develop two in-vitro
diagnostic (IVD) test kits for use on Illumina's sequencing
instruments, including kits for the detection and characterization
of tumor DNA using both tissue and plasma samples.
Doug Ward, Chief Executive
Officer of PGDx, noted, "PGDx currently offers advanced genomic
testing services to researchers, drug developers, and physicians
and patients through our CLIA-certified laboratory. We now want to
apply our expertise to the development of IVD test kits for both
tissue and plasma-based samples that will enable other laboratories
with next-generation sequencing (NGS) capability to benefit from
our broad experience in cancer genomic testing. Illumina is
universally recognized as the global leader in NGS platforms, and
we are delighted to join forces with them to develop IVD kits for
tissue-based and liquid biopsy cancer genomic testing."
"Illumina welcomes the opportunity to work with a diverse set of
leading collaborators, such as PGDx, to ensure that patients have
access to the IVD tests that best address their needs," said John
Leite PhD, Vice President of Market Development and Product
Marketing for Oncology at Illumina. "PGDx is a well-known pioneer
in cancer genomics with deep roots in academic medicine."
PGDx offers a complete range of cancer genome analysis tools,
including exome and targeted approaches for tissue specimens,
targeted approaches for plasma samples and a variety of custom
tissue and plasma-based options designed to address the specific
research needs of cancer researchers and drug developers. It was
established in 2010 by researchers from Johns
Hopkins University who are pioneers in cancer genome
sequencing and liquid biopsy technologies. Under the leadership of
founders Drs. Luis Diaz and Victor
Velculescu, the company has achieved consistent growth by
successfully commercializing novel clinical and investigational
products and services for researchers, drug developers, molecular
testing laboratories and physicians and patients. PGDx's service
offerings for researchers and testing labs are complemented by the
clinical services it provides through its CLIA-certified
laboratory.
About Personal Genome Diagnostics
Personal Genome
Diagnostics (PGDx) advances the frontiers of cancer medicine
through innovative genomic technologies for oncology researchers,
drug developers, clinicians and patients. The expert team at PGDx
draws on a deep understanding of cancer biology, extensive
experience in cancer genomics and clinical oncology, and the
company's distinctive technologies. These novel technologies
precisely identify and characterize unique genomic alterations in
tumors. PGDx is working toward broad patient access to its genomic
approaches, through a CLIA-certified facility providing
comprehensive genomic services, as well as a technology transfer
solution enabling other molecular laboratories to easily
internalize testing. For additional information, visit
www.personalgenome.com.
Contacts
|
|
PGDx
Corporate:
|
Media:
|
Melody
Gretz
|
Barbara
Lindheim
|
973
598-5515
|
BLL Partners
LLC
|
mgretz@personalgenome.com
|
212
584-2276
|
|
blindheim@bllbiopartners.com
|
Logo - http://photos.prnewswire.com/prnh/20150112/168424LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/personal-genome-diagnostics-to-collaborate-with-illumina-on-development-of-cancer-in-vitro-diagnostic-test-kits-300310163.html
SOURCE Personal Genome Diagnostics Inc.